An overview of novel symptomatic treatments for Parkinson’s disease

Fabrizio Stocchi, MD, PhD, IRCCS San Raffaele Rome, Sapienza University of Rome, Italy, provides an overview of emerging symptomatic treatments for Parkinson’s disease (PD). Three new therapies, sublingual apomorphine and two new techniques of levodopa subcutaneous infusion, are expected to be available in 2024 for patients with PD in the United States and Europe. Two drugs - JM-010 and mesdopetam - are in late-stage clinical development for the management of dyskinesia associated with long-term levodopa use. Additional studies of dopamine agonists, including D1/D5 receptor partial agonists and D3 partial agonists, continue to show promise as alternative or adjunctive treatments to levodopa. Novel co-polymer-based drug delivery systems have been tested in animal models with dopamine agonists, ropinirole and rotigotine, and may reduce the number of doses required to sustain continuous levels of dopaminergic agents. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.